Home / Cell Viability/Proliferation Assays / Resazurin

Resazurin

Catalog #: AR002
35 Citations 4 Reviews Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
AR002
Product Details
Citations (35)
FAQs
Supplemental Products
Reviews (4)
Summary Product Datasheets

Resazurin Summary

Resazurin

Resazurin can be utilized as a simple and quantitative method for measuring cell proliferation, viability, and cytotoxicity. It is a non-toxic, water soluble, redox-sensitive dye that changes from its blue/non-fluorescent state to a pink/highly-fluorescent state upon reduction by viable cells. Fluorescence can be read using 544 nm excitation and 590 nm emission wavelengths, or absorbance can be read using a spectrophotometer set at 570 nm.

Label: Resazurin changes from blue/non-fluorescent to pink/highly-fluorescent
Testing Format: Microplate reader
Sample Type: Cultured cells
Size: 100 mL

Specifications

Shipping Conditions
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
Store the unopened product at 2 - 8 °C. Protect from light. Do not use past expiration date.

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Citations for Resazurin

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

35 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. HAF Prevents Hepatocyte Apoptosis and Hepatocellular Carcinoma through Transcriptional Regulation of the NF-?B pathway
    Authors: Pilarte, KA;Reichert, EC;Green, YS;Halberg, LM;McFarland, SA;Mimche, PN;Golkowski, M;Kamdem, SD;Maguire, KM;Summers, SA;Maschek, JA;Reelitz, JW;Cox, JE;Evason, KJ;Koh, MY;
    bioRxiv : the preprint server for biology  2024-01-11
  2. Reengineering Ponatinib to Minimize Cardiovascular Toxicity
    Authors: AP Hnatiuk, AAN Bruyneel, D Tailor, M Pandrala, A Dheeraj, W Li, R Serrano, DAM Feyen, MM Vu, P Amatya, S Gupta, Y Nakauchi, I Morgado, V Wiebking, R Liao, MH Porteus, R Majeti, SV Malhotra, M Mercola
    Cancer Research, 2022-08-03;82(15):2777-2791.  2022-08-03
  3. RNA splicing is a key mediator of tumour cell plasticity and a therapeutic vulnerability in colorectal cancer
    Authors: AE Hall, SÖ Pohl, P Cammareri, S Aitken, NT Younger, M Raponi, CV Billard, AB Carrancio, A Bastem, P Freile, F Haward, IR Adams, JF Caceres, P Preyzner, A von Kriegs, MG Dunlop, FV Din, KB Myant
    Nature Communications, 2022-05-19;13(1):2791.  2022-05-19
  4. Proteomic Assessment of Extracellular Vesicles from Canine Tissue Explants as a Pipeline to Identify Molecular Targets in Osteosarcoma: PSMD14/Rpn11 as a Proof of Principle
    Authors: AK Luu, M Cadieux, M Wong, R Macdonald, R Jones, D Choi, M Oblak, B Brisson, S Sauer, J Chafitz, D Warshawsky, GA Wood, AM Viloria-Pe
    International Journal of Molecular Sciences, 2022-03-17;23(6):.  2022-03-17
  5. HER2?+?breast cancers evade anti-HER2 therapy via a switch in driver pathway
    Authors: AE Smith, E Ferraro, A Safonov, CB Morales, EJA Lahuerta, Q Li, A Kulick, D Ross, DB Solit, E de Stanchi, J Reis-Filho, N Rosen, J Arribas, P Razavi, S Chandarlap
    Nature Communications, 2021-11-18;12(1):6667.  2021-11-18
  6. Frequent Epigenetic Inactivation of DIRAS-1 and DIRAS-2 Contributes to Chemo-Resistance in Gliomas
    Authors: T Rothhammer, F Liesenberg, N Hansen, S Hoja, S Delic, G Reifenberg, MJ Riemenschn
    Cancers, 2021-10-12;13(20):.  2021-10-12
  7. Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma
    Authors: M Tóth, L Wehling, L Thiess, F Rose, J Schmitt, SME Weiler, C Sticht, C De La Torr, M Rausch, T Albrecht, N Grabe, L Duwe, JB Andersen, BC Köhler, C Springfeld, A Mehrabi, Y Kulu, P Schirmache, S Roessler, B Goeppert, K Breuhahn
    BMC Cancer, 2021-10-06;21(1):1079.  2021-10-06
  8. Specific Compositions of Cannabis sativa Compounds Have Cytotoxic Activity and Inhibit Motility and Colony Formation of Human Glioblastoma Cells In Vitro
    Authors: H Peeri, N Shalev, AC Vinayaka, R Nizar, G Kazimirsky, D Namdar, SM Anil, E Belausov, C Brodie, H Koltai
    Cancers, 2021-04-05;13(7):.  2021-04-05
  9. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma
    Authors: X Zhao, MY Wang, H Jiang, T Lwin, PM Park, J Gao, MB Meads, Y Ren, T Li, J Sun, NA Fahmi, S Singh, L Sehgal, X Wang, AS Silva, EM Sotomayor, KH Shain, JL Cleveland, M Wang, W Zhang, J Qi, BD Shah, J Tao
    Cell Reports, 2021-03-16;34(11):108870.  2021-03-16
  10. Cardiac pericytes function as key vasoactive cells to regulate homeostasis and disease
    Authors: LL Lee, AY Khakoo, V Chintalgat
    FEBS Open Bio, 2020-12-14;0(0):.  2020-12-14
  11. IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B�cells
    Authors: J Lee, ME Robinson, N Ma, D Artadji, MA Ahmed, G Xiao, T Sadras, G Deb, J Winchester, KN Cosgun, H Geng, LN Chan, K Kume, TP Miettinen, Y Zhang, MA Nix, L Klemm, CW Chen, J Chen, V Khairnar, AP Wiita, A Thomas-Tik, M Farzan, JU Jung, DM Weinstock, SR Manalis, MS Diamond, N Vaidehi, M Müschen
    Nature, 2020-11-04;0(0):.  2020-11-04
  12. Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines
    Authors: LM Braun, S Lagies, J Guenzle, S Fichtner-F, UA Wittel, B Kammerer
    Cells, 2020-05-19;9(5):.  2020-05-19
  13. Fluorescence-guided fiber-optic micronavigation using microscopic identification of vascular boundary of liver segment and tumors
    Authors: Q Wang, B Qian, M Schäfer, W Gro beta, A Mehrabi, E Ryschich
    Theranostics, 2020-05-15;10(14):6136-6148.  2020-05-15
  14. Exploration of icariin analog structure space reveals key features driving potent inhibition of human phosphodiesterase-5
    Authors: Y Chau, FS Li, O Levsh, JK Weng
    PLoS ONE, 2019-09-20;14(9):e0222803.  2019-09-20
  15. Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma
    Authors: B Goeppert, M Renner, S Singer, T Albrecht, Q Zhang, A Mehrabi, A Pathil, C Springfeld, B Köhler, C Rupp, KH Weiss, AA Kühl, R Arsenic, UF Pape, A Vogel, P Schirmache, S Roessler, N Utku
    Sci Rep, 2019-03-13;9(1):4338.  2019-03-13
  16. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas
    Authors: Y Ren, C Bi, X Zhao, T Lwin, C Wang, J Yuan, AS Silva, BD Shah, B Fang, T Li, JM Koomen, H Jiang, JC Chavez, L Pham, PR Sudalagunt, L Wan, X Wang, WS Dalton, LC Moscinski, KH Shain, J Vose, JL Cleveland, EM Sotomayor, K Fu, J Tao
    J. Clin. Invest., 2018-11-05;0(0):.  2018-11-05
  17. The autophagy inhibitor spautin-1, either alone or combined with doxorubicin, decreases cell survival and colony formation in canine appendicular osteosarcoma cells
    Authors: CR Schott, L Ludwig, AJ Mutsaers, RA Foster, GA Wood
    PLoS ONE, 2018-10-29;13(10):e0206427.  2018-10-29
  18. Functional 3D Human Liver Bud Assembled from MSC-Derived Multiple Liver Cell Lineages
    Authors: J Li, F Xing, F Chen, L He, KF So, Y Liu, J Xiao
    Cell Transplant, 2018-06-13;0(0):9636897187803.  2018-06-13
  19. KMT2C mediates the estrogen dependence of breast cancer through regulation of ER? enhancer function
    Authors: K Gala, Q Li, A Sinha, P Razavi, M Dorso, F Sanchez-Ve, YR Chung, R Hendrickso, J Hsieh, M Berger, N Schultz, A Pastore, O Abdel-Waha, S Chandarlap
    Oncogene, 2018-05-14;0(0):.  2018-05-14
  20. Chronophin regulates active vitamin B6 levels and transcriptomic features of glioblastoma cell lines cultured under non-adherent, serum-free conditions
    Authors: M Schulze, M Hutterer, A Sabo, S Hoja, J Lorenz, T Rothhammer, C Herold-Men, L Flo beta bach, C Monoranu, MJ Riemenschn
    BMC Cancer, 2018-05-03;18(1):524.  2018-05-03
  21. The EphB6 receptor is overexpressed in pediatric T cell acute lymphoblastic leukemia and increases its sensitivity to doxorubicin treatment.
    Authors: Amr El Zawily, Emily McEwen, Behzad Toosi, Frederick S Vizeacoum, Tanya Freywald, Franco J Vizeacoum, Andrew Freywald
    Scientific Reports, 2017-11-07;0(0):2045-2322.  2017-11-07
  22. Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases
    Elife, 2016-12-09;5(0):.  2016-12-09
  23. A Novel Non-Peptidic Agonist of the Ghrelin Receptor with Orexigenic Activity In vivo
    Sci Rep, 2016-11-07;6(0):36456.  2016-11-07
  24. Cytotoxic effects of tetracycline analogues (doxycycline, minocycline and COL-3) in acute myeloid leukemia HL-60 cells.
    Authors: Song H, Fares M, Maguire K, Siden A, Potacova Z
    PLoS ONE, 2014-12-15;9(12):e114457.  2014-12-15
  25. Devil's Claw to suppress appetite--ghrelin receptor modulation potential of a Harpagophytum procumbens root extract.
    Authors: Torres-Fuentes C, Theeuwes W, McMullen M, McMullen A, Dinan T, Cryan J, Schellekens H
    PLoS ONE, 2014-07-28;9(7):e103118.  2014-07-28
  26. Development and characterization of an antibody-labeled super-paramagnetic iron oxide contrast agent targeting prostate cancer cells for magnetic resonance imaging.
    Authors: Bates D, Abraham S, Campbell M, Zehbe I, Curiel L
    PLoS ONE, 2014-05-12;9(5):e97220.  2014-05-12
  27. Chitinases are negative regulators of Francisella novicida biofilms.
    Authors: Chung, Myung-Ch, Dean, Scott, Marakasova, Ekaterin, Nwabueze, Albert O, van Hoek, Monique
    PLoS ONE, 2014-03-24;9(3):e93119.  2014-03-24
  28. Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine.
    Authors: Ehsanipour E, Sheng X, Behan J, Wang X, Butturini A, Avramis V, Mittelman S
    Cancer Res, 2013-04-12;73(10):2998-3006.  2013-04-12
  29. Circulating alphaKlotho influences phosphate handling by controlling FGF23 production.
    Authors: Smith R
    J. Clin. Invest., 2012-11-26;122(12):4710-5.  2012-11-26
  30. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death.
    Authors: Gammoh N, Lam D, Puente C
    Proc. Natl. Acad. Sci. U.S.A., 2012-04-09;109(17):6561-5.  2012-04-09
  31. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer.
    Authors: Jalava S, Urbanucci A, Latonen L, Waltering K, Sahu B, Janne O, Seppala J, Lahdesmaki H, Tammela T, Visakorpi T
    Oncogene, 2012-01-23;31(41):4460-71.  2012-01-23
  32. EphB receptors trigger Akt activation and suppress Fas receptor-induced apoptosis in malignant T lymphocytes.
    Authors: Maddigan A, Truitt L, Arsenault R
    J. Immunol., 2011-10-28;187(11):5983-94.  2011-10-28
  33. Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells.
    Authors: O'Callaghan G, Kelly J, Shanahan F, Houston A
    Br. J. Cancer, 2008-07-22;99(3):502-12.  2008-07-22
  34. Expression of bioactive single-chain murine IL-12 in transgenic plants.
    Authors: Liu J, Dolan MC, Reidy M, Cramer CL
    J. Interferon Cytokine Res., 2008-06-01;28(0):381-92.  2008-06-01
  35. 2-Methoxy antimycin reveals a unique mechanism for Bcl-x(L) inhibition.
    Authors: Schwartz PS, Manion MK, Emerson CB, Fry JS, Schulz CM, Sweet IR, Hockenbery DM
    Mol. Cancer Ther., 2007-07-01;6(7):2073-80.  2007-07-01

FAQs

  1. What is the concentration of Resazurin, Catalog # AR002? 

    • The concentration of Resazurin is 0.1 mg/mL.

View all Activity Assay FAQs
Loading...

Reviews for Resazurin

Average Rating: 4.8 (Based on 4 Reviews)

5 Star
75%
4 Star
25%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Resazurin?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Resazurin
By Anonymous on 07/02/2021
Resazurin AR002
Resazurin
By Anonymous on 02/20/2021

very easy to use.

Resazurin
By Anonymous on 03/26/2018
Resazurin
By Oonagh Paerewijck on 02/15/2018

Different concentrations of cells

Resazurin AR002